

# Daniel Rooks

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2931994/publications.pdf>

Version: 2024-02-01

13  
papers

3,288  
citations

840585

11  
h-index

1199470

12  
g-index

13  
all docs

13  
docs citations

13  
times ranked

4826  
citing authors

#	ARTICLE	IF	CITATIONS
1	Establishing the Link Between Lean Mass and Grip Strength Cut Points With Mobility Disability and Other Health Outcomes: Proceedings of the Sarcopenia Definition and Outcomes Consortium Conference. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 1317-1323.	1.7	91
2	Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 1525-1534.	2.9	15
3	Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults. <i>JAMA Network Open</i> , 2020, 3, e2020836.	2.8	71
4	Sarcopenia Definition: The Position Statements of the Sarcopenia Definition and Outcomes Consortium. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1410-1418.	1.3	347
5	Developing and Implementing Performance Outcome Assessments: Evidentiary, Methodologic, and Operational Considerations. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, 53, 146-153.	0.8	24
6	Sarcopenia: a Muscle Disease with Decreased Functional Capacity and an Increased Risk of Adverse Health Outcomes. <i>Current Physical Medicine and Rehabilitation Reports</i> , 2019, 7, 290-296.	0.3	1
7	DEVELOPMENT OF PHARMACOTHERAPIES FOR THE TREATMENT OF SARCOPENIA. <i>Journal of Frailty &amp; Aging, the</i> , 2019, 8, 1-11.	0.8	31
8	Continuous Digital Monitoring of Walking Speed in Frail Elderly Patients: Noninterventional Validation Study and Longitudinal Clinical Trial. <i>JMIR MHealth and UHealth</i> , 2019, 7, e15191.	1.8	39
9	Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes. <i>Clinical Endocrinology</i> , 2018, 88, 908-919.	1.2	18
10	Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 94-102.	2.2	59
11	Reply to: New Hope for Sarcopenia. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 208-209.	1.3	0
12	Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 1988-1995.	1.3	165
13	Sarcopenia: An Undiagnosed Condition in Older Adults. Current Consensus Definition: Prevalence, Etiology, and Consequences. International Working Group on Sarcopenia. <i>Journal of the American Medical Directors Association</i> , 2011, 12, 249-256.	1.2	2,427